CytoDyn (CYDY) Upgraded at Zacks Investment Research

CytoDyn (OTCMKTS:CYDY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Friday. The brokerage currently has a $0.50 price target on the biotechnology company’s stock.

According to Zacks, “CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in humans and is currently in Phase 3 development. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy. “

CYDY has been the topic of a number of other reports. HC Wainwright set a $2.00 price target on CytoDyn and gave the company a “buy” rating in a report on Tuesday, March 5th. ValuEngine downgraded CytoDyn from a “buy” rating to a “hold” rating in a report on Friday, December 21st.

OTCMKTS CYDY traded down $0.02 on Friday, reaching $0.50. 839,413 shares of the stock traded hands, compared to its average volume of 471,073. The firm has a market cap of $150.74 million, a PE ratio of -1.72 and a beta of 0.41. CytoDyn has a 12 month low of $0.06 and a 12 month high of $0.71.

About CytoDyn

CytoDyn Inc, a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease.

Recommended Story: Why are percentage gainers important?

Get a free copy of the Zacks research report on CytoDyn (CYDY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with's FREE daily email newsletter.